- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02268812
Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain. (PRIME)
Patient Registry of Intrathecal Pain Management in Europe: An Open-label, Long-term, Multi-center, Multi-national Post-marketing Observational Study of the Use of Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria
Patients will be eligible to enroll onto the registry if they have given informed consent and meet the following criteria:
- Patient's physician has deemed that the initiation/switch of intrathecal analgesia appropriate, or patient is presently utilizing ziconotide (Prialt)
- Patient has a diagnosis of severe, chronic pain for which intrathecal infusion is indicated
- Patient is at least 18 years of age at time of study entry
All patients starting ziconotide (Prialt) should comply with the indications and warnings in the current approved version of the Summary of Product Characteristics (SmPC).
Exclusion Criteria
Patients who meet any of the following criteria will not be eligible to enroll in the registry:
- Patient is a pregnant or lactating female
- Patient is receiving intrathecal chemotherapy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Ziconotide
No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry. IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Overall Change From Baseline (Visit 1) in Visual Analog Scale of Pain Intensity (VASPI)
Time Frame: Month 8 (Visit 4), Month 12 (Visit 5), and Termination Visit (12 months after last participant was enrolled)
|
VASPI is a worldwide validated measure of pain intensity.
A Visual Analog Score (VAS) for pain is determined by using a horizontal line, 100-millimeter (mm) in length, anchored by word descriptors at each end; "no pain" (0 mm) on the left end and "worst imaginable pain" (100 mm) on the right end.
The participant was asked to mark on the line the point that they feel represents their current state of pain.
A VAS for least pain (over last two weeks), usual pain (over last two weeks), and pain today was determined and averaged to derive the total VAS score ranging from 0 (no pain) to 100 (worst pain imaginable).
A last observation carried forward (LOCF) dataset was used to account for missing data where First Visit data could be carried forward.
|
Month 8 (Visit 4), Month 12 (Visit 5), and Termination Visit (12 months after last participant was enrolled)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Month 12 (Visit 5)
Time Frame: Baseline (Visit 1) to Month 12 (Visit 5)
|
The Brief Pain Inventory-Short Form (BPI-SF) survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g.
mood, walking ability, relations with other people, enjoyment of life, etc.).
Each item was graded on an 11-point Likert scale.
The pain intensity/severity survey was used to measure pain severity, where 0 was "no pain" and 10 was "pain as bad as you can imagine" for each item listed.
The pain interference survey scored each item on a scale, where 0 was "does not interfere" to 10 was "completely interferes".
The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores.
|
Baseline (Visit 1) to Month 12 (Visit 5)
|
Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Termination Visit
Time Frame: Baseline (Visit 1) to Termination Visit (12 Months after last participant was enrolled)
|
The BPI-SF survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g.
mood, walking ability, relations with other people, enjoyment of life, etc.).
Each item was graded on an 11-point Likert scale.
The pain intensity/severity survey was used to measure pain severity, where 0 was "no pain" and 10 was "pain as bad as you can imagine" for each item listed.
The pain interference survey scored each item on a scale, where 0 was "does not interfere" to 10 was "completely interferes".
The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores.
|
Baseline (Visit 1) to Termination Visit (12 Months after last participant was enrolled)
|
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
Time Frame: From first dose up to 30 days after the last dose of study treatment, for up to approximately 4 years 4 months.
|
Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events (SAEs), any therapeutic interventions including all drug therapies, vital signs, and creatine kinase (CK) if laboratory tests were taken by the physician as part of routine clinical practice.
AEs were graded on a 3-point scale; 1) mild - discomfort noticed, but no disruption of normal daily activity, 2) moderate - discomfort sufficient to reduce or affect normal daily activity, 3) severe - incapacitating, with inability to work or to perform normal daily activity.
A TEAE was defined as an adverse event (AE) with a start date on or after the date of the First Visit.
Where a start date was missing, the AE was considered to be treatment-emergent.
|
From first dose up to 30 days after the last dose of study treatment, for up to approximately 4 years 4 months.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Primary Intrathecal Drug, Including Dose Adjustment and Intervals
Time Frame: 12 months after the last patient was enrolled
|
Data for this outcome measure was collected as part of the participant's study visit, however was not analyzed as an efficacy endpoint for reporting.
|
12 months after the last patient was enrolled
|
Change in the Actual Overall EuroQoL (EQ-5D) Health Score From First Visit to Month 12 and End of Study
Time Frame: Month 12 Visit, End of Study (Termination Visit)
|
The EQ-5D is a standardized instrument used to measure quality of life.
It classifies health states across five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression.
Each domain has three levels (no problems, some/moderate problems, extreme problems).
A unique EQ-5D health state was defined by combining one level from each of the five dimensions.
The response to the question of how good or bad the participant's health was today was given on a visual analogue scale of 0 to 100 millimeters (mm), where 0 meant the participant was in the worst imaginable health state today and 100 meant the participant was in the best imaginable health state today.
The results for the Health Score were that of the calculated overall score of the five dimensions, where -0.594 is worst health and 1.00 is perfect health.
Change is defined as change in actual from the First Visit.
|
Month 12 Visit, End of Study (Termination Visit)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNX-111-E044-401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain Management
-
Assiut UniversityNot yet recruitingPain Management | Neonates Pain Management
-
Wolfson Medical CenterUnknownPain Management | Post Surgical Management | Inflamation ManagementIsrael
-
Sintetica SACross S.A.CompletedPhase 1: Pain Management | Phase 2: Pain ManagementSwitzerland
-
Värmland County Council, SwedenSykehuset Telemark; Örebro University, Sweden; Dalarna County Council, Sweden; Region... and other collaboratorsCompletedInfant Pain Management | Parent-driven Pain ManagementSweden
-
Cedars-Sinai Medical CenterCompletedImmersive Virtual Reality Intervention for Non-Opioid Pain Management: A Randomized Controlled TrialPain | Pain ManagementUnited States
-
VA Office of Research and DevelopmentCompleted
-
Uludag UniversityRecruiting
-
The University of Texas Health Science Center at...Recruiting
-
Carilion ClinicChorda Pharma, Inc.Completed
-
Parkland Health and Hospital SystemCompletedPain ManagementUnited States